A sustained immunologic response was observed, with most patients experiencing CD4 recovery above 200 cells/μL, a clinically meaningful threshold for clinical progression and opportunistic infections (OI) [16], [17]. This evidence concerns the gene CD4 and osteogenesis imperfecta.